Weakness, dizziness, ataxia, headache, drowsiness, insomnia, and change in mood or mental state such as depression or confusion have also been reported. Peripheral neuropathy, usually presenting as numbness or tingling in the extremities, and epileptic seizures have been associated with high doses of metronidazole or prolonged treatment.
Temporary moderate leucopenia and thrombocytopenia may occur in some patients receiving metronidazole. Skin rashes, urticaria, and pruritus occur occasionally and erythema multiform, angioedema and anaphylaxis have been reported rarely. Other adverse effects include urethral discomfort and darkening of the urine. Raised liver enzyme values, cholestatic hepatitis, and jaundice have occasionally been reported.
Thrombophlebitis may follow the intravenous administration of metronidazole.
Studies have shown metronidazole to be mutagenic in bacteria and carcinogenic in some animals.
View ADR Monitoring Form